Outcomes following use of subcutaneous c1-inhibitor during pregnancy in patients with hereditary angioedema

In women with hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency, pregnancy can have a variable effect on disease activity. C1-INH concentrate is recommended as first-line therapy for pregnant patients with HAE. Subcutaneous C1-INH (HAEGARDA ®, CSL Behring) is indicated for routine prophylaxis to prevent HAE attacks in adolescents and adults. This analysis examines outcomes in patients who became pregnant during C1-INH (SC) treatment in an open-label safety study.

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Levy, A. Banerji, M. Cicardi, H. Feuersenger, J. Chiao, I. Pragst, I. Jacobs Tags: P150 Source Type: research